ArticleRomanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
Evaluation of the functional profile of bronchopulmonary cancer patients based on biomarkers in relation to the International Classification of Functioning, Disability and Health.
Article in Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the Scan: Adapting Multimodal Lung Cancer Screening for Central and Eastern Europe-Overcoming Systemic Barriers and Epidemiological Confounders.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with lung cancer commonly report a broad spectrum of symptoms driven by both side effects of treatment and aggressive progression of disease. As a result, growing evidence indicates that pulmonary rehabilitation (PR) can meaningfully improve exercise performance, health-related quality of life (QoL), fatigue, and dyspnea. The core objective of any PR program is to improve the patient's overall functional profile. In this study conducted at the Marius Nasta Institute of Pneumophthisiology, Bucharest, Romania, we assessed the functional profile of patients with non-small cell lung cancer (NSCLC) - specifically lung adenocarcinoma (LUAD) and squamous cell carcinoma (SCC) - and explored its relationship with key biomarkers: programmed death-ligand 1 (PD-L1), anaplastic lymphoma kinase (ALK), and epidermal growth factor receptor (EGFR). Functional status was evaluated using the International Classification of Functioning, Disability, and Health-Rehabilitation Core Set (ICF-RCS). Exercise capacity was measured with the 6-Minute Walk Distance (6MWD) test, health-related QoL was evaluated using the validated European Organization for the Research and Treatment of Cancer Core Quality of Life 30-item Questionnaire (EORTC QLQ-C30) questionnaire and anxiety levels were assessed with the Generalized Anxiety Disorder 7-item (GAD-7) instrument. The study identified a correlation between the patients' functional profiles and specific biomarker patterns. Based on these findings, we believe that incorporating biomarker information into functional evaluation could help build a clearer and more clinically relevant understanding of patient needs during PR, ultimately contributing to more personalized comprehensive care. We propose that future research should examine whether the relationship between biomarker status and functional, psychological, and QoL outcomes remains consistent following a structured rehabilitation program, and whether these biological markers can predict which patients are most likely to experience functional and emotional improvements. Such insight could prove valuable in guiding individualized rehabilitation strategies for patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.